Table 1.
Characteristics of the 13 included studies evaluating the diagnostic performance of miR-122 for HCC.
| Author, year | Country | Number of HCC patients | Mean age (years) of HCC patients | Male (%) among HCC patients | Control population | Number of controls | Mean age (years) of controls | Male (%) among controls | Sample type | miRmeasurement method | QUADAS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Xu, 2011 [12] | China | 101 | NR | 77.2 | HC | 89 | NR | 76.4 | Serum | RT-qPCR | 9 |
| Qi, 2011 [11] | China | 70 | 49.0 | 78.6 | HBV, HC | 82 | 42.0 | 74.1 | Serum | RT-qPCR | 9 |
| Luo, 2013 [13] | China | 85 | 53.9 | 82.4 | HBV, HC | 85 | 50.8 | 81.2 | Serum | RT-qPCR | 8 |
| Tan, 2014 [14] | China | 135 | 53.6 | 83.0 | LC, HBV | 222 | 40.5 | 68.2 | Serum | RT-qPCR | 10 |
| El-Garem, 2014 [16] | Egypt | 30 | 60.3 | 83.3 | LC | 30 | 55.1 | 70.0 | Serum | RT-qPCR | 6 |
| Hung, 2016 [17] | China | 120 | 58.5 | 80.0 | DN | 30 | 60.3 | 80.0 | Serum | RT-qPCR | 11 |
| Ali, 2017 [18] | Egypt | 34 | NR | 76.5 | HCV, HC | 77 | NR | 71.6 | Serum | RT-qPCR | 8 |
| Amr, 2017a [19] | Egypt | 40 | 52 | 82.5 | HCV, HC | 60 | 50.0 | 83.0 | Serum | RT-qPCR | 9 |
| Caviglia, 2017 [20] | Italy | 33 | 63.0 | 87.9 | LC | 30 | 54.2 | 63.3 | Serum | RT-qPCR | 11 |
| Trung, 2018 [22] | Vietnam | 118 | 55.6 | 91.2 | LC, HBV, HC | 288 | 43.1 | 81.6 | Serum | RT-qPCR | 11 |
| An, 2018 [21] | China | 84 | 52.7 | 67.8 | HC | 84 | 51.5 | 59.7 | Serum | RT-qPCR | 8 |
| Weis, 2019 [24] | Australia | 20 | 58.3 | 75.0 | LC | 40 | 51.9 | 67.5 | Serum | RT-qPCR | 12 |
| Dai, 2019 [23] | China | 50 | 48.6 | 70.0 | LC, HBV, HC | 100 | 46.1 | 70.0 | Serum | RT-qPCR | 8 |
HCC: hepatocellular carcinoma; NR: not reported; HC: healthy controls; HBV: hepatitis B virus infection; HCV: hepatitis C virus infection; LC: liver cirrhosis; DN: dysplastic nodule; RT-qPCR: reverse transcription quantitative real-time polymerase chain reaction; QUADAS: Quality Assessment of Diagnostic Accuracy Studies.